Contract analysis

I. Executive Summary The purpose of this memorandum is to evaluate whether any violations of the federal Anti-Kickback Statute ("AKS"), 42 U.S.C. § 1320a-7b(b), identified during the Calderwood & Harkness self-assessment engagement (opened January 30, 2023) warrant voluntary self-disclosure by Arbor Health Technologies Inc. ("AHT") to the United States Department of Health and Human Services Office of Inspector Gener

1. Meridian Diagnostics LLC Per-Scan Facility Access Fee. A services agreement under which Meridian Diagnostics LLC pays AHT a per-scan facility access fee of $185 per scan for use of AHT clinic space in Connecticut, resulting in $777,000 in fee revenue to AHT in FY2022 alongside approximately $2.8 million in referrals from AHT physicians to Meridian. The per-scan fee structure varies directly with the volume of scan

2. Pinnacle Laboratory Services Inc. No-Cost Electronic Lab Interface and CME Sponsorship. A preferred laboratory agreement under which Pinnacle provides AHT with a no-cost electronic laboratory interface (estimated market value: $120,000 per year) and sponsored four continuing medical education ("CME") events for AHT physicians totaling $86,000 in FY2022, in the context of approximately $1.65 million in annual refer

3. Above-FMV Medical Director Compensation (38 Arrangements). AHT maintains thirty-eight (38) independent contractor / medical director arrangements across its 23-clinic network, with aggregate annual compensation of $1.92 million and an effective average hourly rate of $501.28 per hour — a figure that exceeds the 90th percentile for multiple physician specialties based on MGMA and SullivanCotter benchmark data, as c

II. Background A. AHT Overview Arbor Health Technologies Inc. ("AHT") is a Delaware corporation headquartered at 200 Concord Avenue, Suite 400, Cambridge, Massachusetts 02138. AHT operates a network of twenty-three (23) outpatient clinics, branded as "Arbor Health Clinics," across four states in New England. The clinic distribution is as follows: fourteen (14) clinics in Massachusetts, four (4) clinics in Connecticut

III. OIG Self-Disclosure Protocol — Legal Framework A. Overview of the OIG SDP The OIG Self-Disclosure Protocol was established by the OIG to provide healthcare providers, suppliers, and other persons subject to the OIG's civil monetary penalty and program exclusion authorities with a mechanism to voluntarily identify, disclose, and resolve potential instances of fraud involving federal healthcare programs, including

1. A detailed description of the conduct giving rise to the disclosure, including the nature of the arrangement(s), the parties involved, and the manner in which the conduct potentially violates applicable federal law.

2. The time period during which the conduct occurred, including the inception date of the arrangement(s) and the date on which the conduct was identified or terminated.

3. The names, titles, and roles of all individuals and entities involved in the conduct, including the disclosing entity, any co-participants, and any individuals who authorized, directed, or were aware of the conduct.

4. A detailed explanation of how the matter was discovered, including whether the discovery resulted from an internal audit, compliance review, whistleblower complaint, or other mechanism.

5. A comprehensive description of all corrective actions taken or planned, including the termination or restructuring of the arrangement(s), changes to policies and procedures, training initiatives, and any personnel actions.

6. A financial analysis estimating the damages or losses to federal healthcare programs resulting from the disclosed conduct. This analysis should include, at a minimum, the total remuneration paid or received in connection with the arrangement(s), the total volume and value of federal healthcare program claims associated with the arrangement(s), and the entity's calculation of the estimated damages.

7. All supporting documentation, including copies of relevant agreements, financial records, organizational charts, correspondence, and any internal or external reports related to the disclosed conduct. The OIG has emphasized that SDP submissions should be thorough, candid, and complete. Incomplete or misleading submissions may result in adverse consequences, including the OIG's decision to refer the matter to DOJ, t

IV. Analysis of Highest-Risk Arrangements A. Meridian Diagnostics LLC — Per-Scan Facility Access Fee

1. Description of the Arrangement. Pursuant to a services agreement dated March 1, 2021, AHT entered into an arrangement with Meridian Diagnostics LLC ("Meridian"), a limited liability company organized under the laws of Connecticut and located at 88 Trumbull Street, Hartford, Connecticut 06103. Under the agreement, Meridian provides mobile MRI and advanced diagnostic imaging services at four of AHT's clinic location

2. AKS Analysis. The Meridian arrangement presents the most significant AKS risk of any arrangement identified in the self-assessment. The core compliance concern is the per-scan fee structure, which means that the compensation paid by Meridian to AHT varies directly with the volume of scans performed at AHT facilities. Because the volume of scans performed at AHT facilities is, in turn, directly correlated with the

3. Intent Analysis. The AKS requires proof that the defendant acted "knowingly and willfully" in soliciting, receiving, offering, or paying remuneration to induce or reward referrals. However, under the "one-purpose test" adopted by the majority of federal circuits, the government need not prove that inducing referrals was the sole or even the primary purpose of the arrangement — it is sufficient to establish that at

4. Estimated Financial Exposure. The period of potential AKS liability for the Meridian arrangement extends from the inception of the current agreement on March 1, 2021, through the present date, a period of approximately twenty-seven (27) months. Calderwood & Harkness estimates the financial exposure as follows: • FY2022 facility access fee revenue: $777,000 (4,200 scans × $185) • Estimated FY2021 facility access fe

5. Assessment. The Meridian per-scan facility access fee arrangement is the highest-risk AKS arrangement identified in the self-assessment. The per-scan fee structure is precisely the type of volume-based compensation that the AKS is designed to address, and the arrangement does not satisfy any applicable safe harbor. The structural incentive for referral generation is clear and direct. However, several mitigating fa

1. Description of the Arrangement. AHT is party to a preferred laboratory agreement dated June 15, 2020, with Pinnacle Laboratory Services Inc. ("Pinnacle"), a clinical laboratory company located at 1200 Warwick Avenue, Suite 110, Warwick, Rhode Island 02886 (EIN: 05-6138290). Under the agreement, AHT clinics in Rhode Island and southeastern Massachusetts refer outpatient laboratory testing to Pinnacle as a preferred

2. AKS Analysis — No-Cost Lab Interface. The provision of a $120,000-per-year technology interface at no cost to AHT constitutes "remuneration" under the AKS. The AKS defines "remuneration" broadly to include "any kickback, bribe, or rebate" and "transfers of anything of value, directly or indirectly, overtly or covertly, in cash or in kind." 42 U.S.C. § 1320a-7b(b). A $120,000 annual benefit provided at no cost by a

3. AKS Analysis — CME Sponsorship. Pinnacle's sponsorship of four CME events totaling $86,000 in FY2022 for AHT physicians raises additional AKS concerns regarding remuneration to referral sources. While the funding of physician education is not inherently prohibited by the AKS, the OIG has repeatedly cautioned that CME sponsorships from entities with existing referral relationships should be carefully structured to

4. AKS Analysis — Dr. Karen Ellsworth's Equity Interest. Dr. Karen Ellsworth's 4.2% passive equity interest in Pinnacle introduces an additional and significant complicating factor to the Pinnacle relationship. Dr. Nathan Ellsworth, as AHT's CEO, has influence — whether direct or indirect — over AHT's referral patterns, laboratory contracting decisions, and preferred vendor relationships. While Dr. Karen Ellsworth is

5. Estimated Financial Exposure. The period of potential AKS liability for the Pinnacle arrangement extends from the inception of the preferred laboratory agreement on June 15, 2020, through the present date, a period of approximately thirty-six (36) months. Calderwood & Harkness estimates the financial exposure as follows: • Value of no-cost lab interface over liability period: approximately $360,000 ($120,000 × 3 y

6. Assessment. The Pinnacle relationship presents a moderate-to-high AKS risk. The no-cost lab interface is the most significant concern, as it represents $120,000 per year in gratuitous remuneration that is functionally linked to a $1.65 million annual referral stream and that creates a lock-in effect reinforcing the referral relationship. The CME sponsorship and the CEO spousal equity interest amplify the risk by c

1. Description of the Arrangements. AHT maintains a total of thirty-eight (38) independent contractor / medical director arrangements across its network of twenty-three outpatient clinics. These arrangements cover a range of clinical and administrative oversight functions, including quality assurance, peer review, utilization management, staff credentialing, regulatory compliance oversight, and clinical protocol deve

2. AKS Analysis. Compensation paid to physicians who are in a position to refer federal healthcare program patients to the payor, and that exceeds fair market value, constitutes potential "remuneration" under the AKS. The excess compensation — the amount by which the physician's compensation exceeds what would be paid in an arm's-length transaction for comparable services — may be viewed as an inducement for the medi